Oncodesign Services Acquires ZoBio; Eurazeo's Nov Santé Invests in Oncodesign
January 23, 2023
Oncodesign Services, majority-held by ERES IV SLP (Edmond de Rothschild Private Equity), has acquired Dutch fragment-based drug discovery specialist ZoBio to strengthen its upstream Drug Discovery capabilities. Concurrently, Nov Santé Actions Non Cotées (managed by Eurazeo) has invested in Oncodesign Services to support external growth and the group's international expansion.
- Buyers
- Oncodesign Services, Nov Santé Actions Non Cotées (Eurazeo), ERES IV SLP / Edmond de Rothschild Private Equity
- Targets
- ZoBio
- Industry
- Biotechnology
- Location
- South Holland, Netherlands
- Transaction Type
- Addon
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.